Back to top

Revolution Medicines price target raised to $235 from $205 at Guggenheim

Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $235 from $205 and keeps a Buy rating on the sh...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Revolution Medicines, Inc. (RVMD)